

Ontuxizumab

| | |
|------------------|---|
| Cat. No.: | HY-P99778 |
| CAS No.: | 946415-62-9 |
| Target: | EGFR |
| Pathway: | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|--------------------|--|---|
| Description | Ontuxizumab (MORAb-004) is a humanized IgG1/ κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer ^[1] . | |
| In Vitro | Ontuxizumab (0-100 μ g/mL; 12 h) induces CD248 internalization and dose-dependently reduces 46% CD248 of cell surface of human pericytes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Human CD248 knock-in mice ^[1] |
| | Dosage: | 50 mg/kg |
| | Administration: | Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days |
| | Result: | Reduced tumor growth with a lower level of CD248 and α -SMA on neovasculature pericytes. |

REFERENCES

[1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. *Oncotarget*. 2015 Sep 22;6(28):25429-40.

[2]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. *Oncotarget*. 2015 Sep 22;6(28):25429-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA